TY - JOUR
T1 - Le modèle de risque du German Hodgkin Study Group est utile pour les patients atteints de lymphome de Hodgkin traités par irradiation après greffe autologue
AU - Furlan, C.
AU - Matrone, F.
AU - Rupolo, M.
AU - Ciancia, R.
AU - Zanet, E.
AU - Montante, B.
AU - Palazzari, E.
AU - Navarria, F.
AU - Trovo, M.
AU - Bulian, P.
AU - Spina, M.
AU - Coassin, E.
AU - Mascarin, M.
AU - De Paoli, A.
AU - Franchin, G.
AU - Michieli, M.
PY - 2019/9
Y1 - 2019/9
N2 - Purpose: To apply the German Hodgkin Study Group (GHSG) risk model in patients with recurrent/refractory Hodgkin lymphoma receiving involved-field radiotherapy after autologous stem cell transplantation. Material and methods: The study consisted in the retrospective analysis of 30 consecutive patients with recurrent/refractory Hodgkin lymphoma who received involved-field radiotherapy after autologous stem cell transplantation. Our policy was of adding involved-field radiotherapy for patients with positive PET scan before autologous stem cell transplantation (23 out of 30 patients, 77%), and/or irradiating sites of bulky disease at relapse (11 out of 30 patients, 37%). Patients were stratified into four risk groups according to the presence of the five clinical risk factors identified by the GHSG; (1) stage IV disease; (2) time to relapse ≤ 3 months; (3) ECOG-PS ≥ 1; (4) bulk ≥ 5 cm; and (5) inadequate response to salvage chemotherapy. Results: The median interval from autologous stem cell transplantation to involved-field radiotherapy was 3 months (range, 1–7 months), and the median involved-field radiotherapy dose was 35 Gy (range, 12–40 Gy). At a median follow-up of 35 months (range, 1–132 months), the 2-year progression-free survival in the entire series was 60%. When examining the four different GHSG risk groups, the progression-free survival rate at 2 years was 86%, 83%, 50%, and 36% for patients with score = 0, score = 1, score = 2, and score = 3 to 5, respectively (P = 0,01). Among the 12 patients having at least three risk factors who underwent thoracic involved-field radiotherapy, three (25%) developed pneumonitis. Conclusion: The adoption of the GHSG risk model at the time of recurrence/progression is a useful prognostic tool to select patients with Hodgkin lymphoma for consolidative involved-field radiotherapy after autologous stem cell transplantation.
AB - Purpose: To apply the German Hodgkin Study Group (GHSG) risk model in patients with recurrent/refractory Hodgkin lymphoma receiving involved-field radiotherapy after autologous stem cell transplantation. Material and methods: The study consisted in the retrospective analysis of 30 consecutive patients with recurrent/refractory Hodgkin lymphoma who received involved-field radiotherapy after autologous stem cell transplantation. Our policy was of adding involved-field radiotherapy for patients with positive PET scan before autologous stem cell transplantation (23 out of 30 patients, 77%), and/or irradiating sites of bulky disease at relapse (11 out of 30 patients, 37%). Patients were stratified into four risk groups according to the presence of the five clinical risk factors identified by the GHSG; (1) stage IV disease; (2) time to relapse ≤ 3 months; (3) ECOG-PS ≥ 1; (4) bulk ≥ 5 cm; and (5) inadequate response to salvage chemotherapy. Results: The median interval from autologous stem cell transplantation to involved-field radiotherapy was 3 months (range, 1–7 months), and the median involved-field radiotherapy dose was 35 Gy (range, 12–40 Gy). At a median follow-up of 35 months (range, 1–132 months), the 2-year progression-free survival in the entire series was 60%. When examining the four different GHSG risk groups, the progression-free survival rate at 2 years was 86%, 83%, 50%, and 36% for patients with score = 0, score = 1, score = 2, and score = 3 to 5, respectively (P = 0,01). Among the 12 patients having at least three risk factors who underwent thoracic involved-field radiotherapy, three (25%) developed pneumonitis. Conclusion: The adoption of the GHSG risk model at the time of recurrence/progression is a useful prognostic tool to select patients with Hodgkin lymphoma for consolidative involved-field radiotherapy after autologous stem cell transplantation.
KW - Hodgkin lymphoma
KW - Radiotherapy
KW - Recurrent
KW - Transplant
UR - http://www.scopus.com/inward/record.url?scp=85066462890&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85066462890&partnerID=8YFLogxK
U2 - 10.1016/j.canrad.2019.02.002
DO - 10.1016/j.canrad.2019.02.002
M3 - Articolo
C2 - 31178272
AN - SCOPUS:85066462890
VL - 23
SP - 378
EP - 384
JO - Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique
JF - Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique
SN - 1278-3218
IS - 5
ER -